Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Acquires $49,800.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger bought 60,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were bought at an average price of $0.83 per share, for a total transaction of $49,800.00. Following the completion of the transaction, the director directly owned 526,991 shares in the company, valued at approximately $437,402.53. This represents a 12.85% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Oncolytics Biotech Stock Up 27.0%

Shares of NASDAQ ONCY opened at $1.06 on Monday. The stock has a market capitalization of $112.52 million, a price-to-earnings ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a 52 week low of $0.33 and a 52 week high of $1.51. The firm has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.07.

More Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Institutional Investors Weigh In On Oncolytics Biotech

A number of institutional investors have recently bought and sold shares of ONCY. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech in the 3rd quarter valued at $535,000. Seeds Investor LLC lifted its position in Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after acquiring an additional 33,826 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at $63,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech during the fourth quarter valued at about $44,000. Finally, Ground Swell Capital LLC acquired a new stake in shares of Oncolytics Biotech during the fourth quarter worth approximately $30,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ONCY shares. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright upped their target price on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.